- Home
- BIRD vs LCTX Comparison
BIRD vs LCTX Comparison
Compare BIRD & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIRD
- LCTX
- Stock Information
- Founded
- BIRD 2015
- LCTX 1990
- Country
- BIRD United States
- LCTX United States
- Employees
- BIRD N/A
- LCTX N/A
- Industry
- BIRD Apparel
- LCTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BIRD Consumer Discretionary
- LCTX Health Care
- Exchange
- BIRD Nasdaq
- LCTX Nasdaq
- Market Cap
- BIRD 99.0M
- LCTX 107.3M
- IPO Year
- BIRD 2021
- LCTX N/A
- Fundamental
- Price
- BIRD $10.50
- LCTX $0.90
- Analyst Decision
- BIRD Buy
- LCTX Strong Buy
- Analyst Count
- BIRD 2
- LCTX 5
- Target Price
- BIRD $9.50
- LCTX $4.20
- AVG Volume (30 Days)
- BIRD 103.8K
- LCTX 2.3M
- Earning Date
- BIRD 08-06-2025
- LCTX 08-07-2025
- Dividend Yield
- BIRD N/A
- LCTX N/A
- EPS Growth
- BIRD N/A
- LCTX N/A
- EPS
- BIRD N/A
- LCTX N/A
- Revenue
- BIRD $182,544,000.00
- LCTX $9,557,000.00
- Revenue This Year
- BIRD N/A
- LCTX N/A
- Revenue Next Year
- BIRD $5.04
- LCTX $232.66
- P/E Ratio
- BIRD N/A
- LCTX N/A
- Revenue Growth
- BIRD N/A
- LCTX 19.42
- 52 Week Low
- BIRD $3.93
- LCTX $0.37
- 52 Week High
- BIRD $18.33
- LCTX $1.15
- Technical
- Relative Strength Index (RSI)
- BIRD 60.59
- LCTX 74.23
- Support Level
- BIRD $10.20
- LCTX $0.67
- Resistance Level
- BIRD $11.68
- LCTX $0.83
- Average True Range (ATR)
- BIRD 1.18
- LCTX 0.06
- MACD
- BIRD 0.10
- LCTX 0.02
- Stochastic Oscillator
- BIRD 61.09
- LCTX 84.94
About BIRD Allbirds Inc.
Allbirds Inc is a lifestyle brand that innovates with naturally derived materials to make footwear and apparel products in a better way, while treading lighter on the planet. Its primary source of revenue is from sales of shoes and apparel products. The majority of the revenue is derived from United States.
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.